BD launches first automated phenotypic test for CPO detection

Fully-automated BD Phoenix™ CPO detect test helps detect dangerous pathogens

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the launch of the first automated phenotypic test to detect and classify carbapenemase-producing organisms (CPO). Available as part of the BD Phoenix™ automated microbiology system in Europe, the new BD Phoenix™ CPO detect test will help hospitals identify and contain infections caused by CPO, while potentially combating an increase in antimicrobial resistance (AMR).

According to the Centers for Disease Control and Prevention (CDC), CPOs, specifically carbapenem-resistant Enterobacteriaceae (CRE), represent a prominent AMR threat to public health because these dangerous microbes may be resistant to nearly all available antibiotics. These organisms are also on the World Health Organization (WHO) priority pathogen list as critical threats to public health. Reported rates of mortality associated with certain CPO infections vary widely from 22 to 72 percent. When CPOs are detected, rapid implementation of infection prevention measures are needed to prevent further transmission.

The BD Phoenix CPO detect test, included on BD Phoenix™ gram-negative panels, identifies CPOs and provides the Ambler classification of the enzyme produced. In contrast to conventional phenotypic methods for CPO detection that can take up to 96 hours, the BD Phoenix™ CPO detect test can detect CPOs accurately in under 36 hours.

The test allows hospitals and laboratories to categorize microbial resistance facilitating the rapid implementation of infection control procedures and the selection of appropriate antibiotics. It provides information that can be used to support hospitals in managing their antimicrobial stewardship programs more effectively.

“The BD Phoenix CPO detect test is a completely new type of phenotypic test, and its range of capabilities is unmatched by all currently marketed tests,” said Kenneth S. Thomson, PhD, FIDSA, FAAM, FASM clinical professor of Pathology and Laboratory Medicine, University of Louisville School of Medicine. “It represents a significant advance in meeting an important clinical need.”

Fully integrated within BD Phoenix panels, the new BD Phoenix CPO detect test enables laboratories to offer a more comprehensive antimicrobial susceptibility test profile while improving laboratory process efficiency. The test is available in two configurations, offering flexibility to customers; a combo panel that detects the presence of CPOs, and the BD Phoenix™ emerge panel that detects the presence of CPOs and if positive, provides the Ambler classification of the carbapenemase.

“The BD Phoenix CPO detect test gives laboratories an accurate and cost-effective method to rapidly identify CPOs and support patient management,” said Steve Conly, vice president of Microbiology for BD. “Along with the BD Phoenix™ M50, this first-to-market phenotypic automated test to detect CPOs, expands BD’s portfolio of solutions for identification and antimicrobial susceptibility testing (ID/AST) and is another example of the company’s commitment to combating AMR.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BD (Becton, Dickinson and Company). (2019, June 19). BD launches first automated phenotypic test for CPO detection. News-Medical. Retrieved on October 16, 2024 from https://www.news-medical.net/news/20170928/BD-launchesc2a0first-automated-phenotypic-test-for-CPO-detection.aspx.

  • MLA

    BD (Becton, Dickinson and Company). "BD launches first automated phenotypic test for CPO detection". News-Medical. 16 October 2024. <https://www.news-medical.net/news/20170928/BD-launchesc2a0first-automated-phenotypic-test-for-CPO-detection.aspx>.

  • Chicago

    BD (Becton, Dickinson and Company). "BD launches first automated phenotypic test for CPO detection". News-Medical. https://www.news-medical.net/news/20170928/BD-launchesc2a0first-automated-phenotypic-test-for-CPO-detection.aspx. (accessed October 16, 2024).

  • Harvard

    BD (Becton, Dickinson and Company). 2019. BD launches first automated phenotypic test for CPO detection. News-Medical, viewed 16 October 2024, https://www.news-medical.net/news/20170928/BD-launchesc2a0first-automated-phenotypic-test-for-CPO-detection.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New BD MAX Check-Points CPO assay receives FDA 510(k) clearance